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Abbreviations 13 
CID   Collision-induced dissociation 14 
ETD   Electron-transfer dissociation  15 
FPLC / HPLC  Fast protein / High pressure liquid chromatography 16 
Gal   Galactose 17 
Gal1   Galectin1 18 
GlcNAc   N-acetylglucosamin 19 
HEK293 cells  Human embryonic kidney cells 20 
HexNAc-Hex  N-acetylhexosamine linked to a hexose 21 
HUVEC   Human umbilical vein endothelial cell 22 
Neu5Ac   N-acetylneuraminic acid 23 
Nrp1   Neuropilin-1 24 
(O-)GalNAc  (O-linked) N-acetylgalactosamine 25 
(RP)-LC-ESI-MS (reversed phase)-liquid chromatography-electrospray ionization mass spectrometry 26 
PGC   porous graphitic carbon 27 
Q-TOF   Quadrupole - Time of flight 28 
SPE   Solid phase extraction 29 
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Abstract 33 
 34 
Neuropilins are involved in angiogenesis and neuronal development. The membrane proximal domain of 35 
neuropilin-1, called c or MAM domain based on its sequence conservation, has been implicated in neuropilin 36 
oligomerization required for its function. The c/MAM domain of human neuropilin-1 has been recombinantly 37 
expressed to allow for investigation of its propensity to engage in molecular interactions with other protein or 38 
carbohydrate components on a cell surface. We found that the c/MAM domain was heavily O-glycosylated with 39 
up to 24 monosaccharide units in the form of disialylated core 1 and core 2 O-glycans. Attachment sites were 40 
identified on the chymotryptic c/MAM peptide ETGATEKPTVIDSTIQSEFPTY by electron-transfer 41 
dissociation mass spectrometry (ETD-MS/MS). For highly glycosylated species consisting of carbohydrate to 42 
about 50%, useful results could only be obtained upon partial desialylation. ETD-MS/MS revealed a hierarchical 43 
order of the initial O-GalNAc addition to the four different glycosylation sites. These findings enable future 44 
functional studies about the contribution of the described glycosylations in neuropilin-1 oligomerization and the 45 
binding to partner proteins as VEGF or galectin-1. 46 
As a spin-off result the sialidase from Clostridium perfringens turned out to discriminate between galactose and 47 
N-acetylgalactosamine linked sialic acid.  48 
 49 
 50 
  51 
3 
 
Introduction 52 
 53 
Neuropilins (Nrps) are a family of transmembrane proteins involved in a number of signaling pathways. Of these 54 
pathways the two best characterized are angiogenesis in combination with the vascular endothelial growth factor 55 
(VEGF) receptor (VEGFR) and neuronal development in combination with plexins. Nrp’s ability to bind to 56 
multiple structurally unrelated ligands has been attributed to its multidomain architecture with a large 57 
ectodomain containing four ligand-binding domains (a1a2b1b2) and a membrain proximal c/MAM domain 58 
purportedly involved in Nrp oligomerization [1].  59 
Nrp’s functionality can also be altered through a post-translational modification on the highly conserved Nrp1 60 
S612, which can be O-glycosylated with either heparan sulphate or chondroitin sulphate [2, 3]. Using a S612A 61 
mutation a number of functional properties have been attributed to this glycan. With the help of I-125 62 
radiolabelled VEGF Shintani [3] and coworkers showed that the glycosylation increases Nrp affinity for VEGF 63 
as well as alters receptor internalization and VEGFR expression levels in smooth muscle cells. Frankel et al [2] 64 
investigated S612 glycosylation effects in highly invasive U87MG human glioma cells and suggested that S612 65 
is modified by chondroitin sulphate exclusively and that loss of this modification is associated with increased 66 
invasion properties of the cells.  Furthermore, they ascribed this behavior to Nrp1-mediated signaling through 67 
p130Cas pathway. S612 is not conserved in Nrp2 thus conferring glycosylation-linked and isoform-specific 68 
properties to Nrp1 only.  Additional N-linked glycosylation sites have been identified on N150, N261 and N522 69 
[4, 5] with two more sites predicted based on sequence analysis (N300 and N842, Uniprot NRP1_HUMAN), 70 
although no functionality has yet been attributed to these putative modifications.   71 
Other roles for glycans associated with neuropilin-1, in both angiogenesis and neuronal development, have also 72 
been postulated.  It has been shown that galectin-1 (Gal1), through its carbohydrate-recognition domain, binds 73 
Nrp1, although the specific carbohydrate and Nrp1 glycosylation site is undetermined [6]. Gal1 is a homo-74 
dimeric lectin with a conserved carbohydrate-binding site capable of binding the β-galactoside units of N- and O-75 
linked sugars [7, 8]. The interaction between Nrp1 and Gal1 increased the migration of HUVEC cells in a 76 
VEGFR-2-dependent fashion [6]. In addition, it has been shown that binding of Gal1 to Nrp1 increases the 77 
phosphorylation levels of VEGFR-2, thus indirectly implicating formation of a complex multiprotein assembly 78 
on the cell surface involving Gal1, glycan-modified Nrp1, VEGF and VEGFR-2. Recently, Quinta et al. [9] has 79 
shown that Gal1 can play an important role in neuronal regeneration. Gal1, through interactions with Nrp1 80 
prevents semaphorin3A from binding to the Nrp1:plexin complex required to induce neuronal growth cone 81 
collapse. Thus, Gal1:Nrp1 interactions have a wide array of cellular effects on different cell types although the 82 
molecular basis of this interaction remains undetermined. 83 
The only well-characterized Nrp1 O-glycosylation site, so far, is S612, a site of covalent attachment for 84 
chondroitin / heparan sulphate. Very recently, 5 O-GalNAc glycosylation sites were reported for Nrp1 but 85 
without specification of the glycan structures [10]. A stretch of clustered O-glycans (4x in a range of 628-646) in 86 
close proximity to the known S612 glycosaminoglycan attachment site might affect the (patho)physiological 87 
properties of this part of Nrp1 (c/MAM domain). Changes in glycan structure and the type of the specific 88 
glycoform of the glycoproteins have been observed in cancer [8, 11-13]. Glycoforms may differ in their affinity 89 
to ligands as exemplified by non-fucosylated IgG [14]. While Nrp1 is known to bind Gal1, the exact site of lectin 90 
binding has not yet been defined and thus knowledge about sites of modifications as well as structures of bound 91 
carbohydrates constitutes an essential basis for further functional studies. Tandem mass spectrometry with 92 
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electron-transfer dissociation (ETD-MS/MS) on an ion trap instrument has recently been applied to the large and 93 
complex multisite O-glycopeptide of bovine fetuin [15] and was therefore considered as an appropriate method 94 
for the analysis of c/MAM. 95 
Here we present a detailed characterization of the O-linked glycosylation of the c/MAM-domain of Nrp1 by 96 
mass spectrometry. The sites of glycosylation (ETD-MS/MS) as well as the chemical structures of the attached 97 
carbohydrates (PGC-LC-MS/MS) were determined revealing a hierarchical order of GalNAc-addition to the 98 
different modification sites. 99 
 100 
 101 
Material and Methods 102 
 103 
cDNA cloning, gene expression and protein purification 104 
A portion of the human Nrp1 cDNA, corresponding to protein residues 628-813 was amplified using the 105 
following primers: 5’-GCGTAGCTGAAACCGGCGCCACAGAAAAGCCCACGGTC-3’, and 5’-106 
GTGGTGGTGGTGTTTTGCTGGTTTTGCACAATCTTCTTGTG-3’. By using the In-Fusion (Clontech Saint-107 
German-en-Laye, France) ligation method, the PCR products were inserted into the pOPINTTGNeo vector 108 
(Oxford Protein Production Facility, UK) to generate pOPINTTGNeo_MAM. The resulting expression construct 109 
encoded a fusion protein that in addition to human Nrp1 c/MAM domain contained an N-terminal secretion tag 110 
and the non-cleavable C-terminal His6-tag.    111 
Protein expression was carried out in HEK293 F cells (Invitrogen, Carlsbad, CA, USA) grown in suspension. 112 
Typically, 1l flasks seeded with 250ml HEK293 F cells at a density of 1.0-1.4 x 106 cells mL-1 were transfected 113 
with 312 µg pOPINTTGNeo_MAM plasmid using 470 µg PEI (Sigma Aldrich, Vienna, Austria) mixed in 10 114 
mL OptiPRO SFM media (Life technologies, Vienna, Austria) supplemented with 4mM L-Glutamine (Sigma 115 
Aldrich).  The cells were grown in FreeStyle expression media (Life technologies) while shaken at 125 rpm in a 116 
CO2 incubator.  3-4 days post transfection the medium was collected and cleared by centrifugation at 3000 g for 117 
15 min, and filtration through 0.45 µm sterile filter. The clarified media was passed through a 1 mL HisTrap FF 118 
column (GE Healthcare, Fairfield, CT, USA) pre-equilibrated with 20 mM Tris-HCl pH 8.0 containing 150 mM 119 
NaCl. The column, mounted on an Äkta Purifier FPLC (GE Healthcare), was washed with equilibration buffer 120 
supplemented with 20 mM imidazole, before the recombinant protein product was eluted in 20 mM Tris-HCl pH 121 
8.0 plus 150 mM NaCl and 500 mM imidazole. The protein was immediately concentrated to about 10 mg/mL 122 
by centrifugation with a 10 kDa cutoff concentrator (Millipore, Vienna, Austria) spun at 4000 x g and subjected 123 
to size exclusion chromatography on a Superdex S200 10/300 GL column (GE Healthcare) equilibrated in 20 124 
mM Tris pH 8.0, 150 mM NaCl. Purified protein eluted from the size exclusion column as a single symmetrical 125 
peak (Supplementary Fig. 1).  No contaminating protein bands were visible in a Coomassie Blue-stained 15 % 126 
SDS-PAGE gel of the eluted fractions corresponding to the main protein peak.  About 1 mg of protein per each 1 127 
L flask were reproducibly generated Removal of the secretion tag by HEK293 cells and the identity of the N-128 
terminal residue were verified by mass spectrometry analysis as described below. The protein was stored in 20 129 
mM Tris pH 8.0, 150 mM NaCl at -80 °C before further analysis. 130 
 131 
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Reductive beta-elimination of O-glycans 132 
O- glycans of the recombinant c/MAM domain (50 µg in 10 µl) were released with 1 M sodium borohydride in 133 
100 mM NaOH  and purified with Hypercarb SPE cartridges (Hypersep Hypercarb, 25 mg, Thermo Scientific, 134 
Vienna). Characterization of these glycans was done via LC-ESI-MS on a porous graphitic carbon (PGC) 135 
column  (100 x 0.32 mm, Hypercarb, Thermo Scientific) using a Dionex Ultimate 3000 nano-HPLC coupled to 136 
an amaZon ion trap (Bruker, Bremen, Germany) as detailed recently [15]. 137 
 138 
Intact mass measurement 139 
The c/MAM-domain (5 µg) was directly taken for an LC-ESI-MS analysis using a Dionex Ultimate 3000 nano-140 
LC system and a Bruker maXis 4G. The protein was run on a C-5 separation column (Discovery BIO Wide Pore 141 
C-5, 50 x 32 mm, 3 µm, Supelco / Sigma Aldrich) at a flow rate of 7 µl /min. After flushing the column for 5 142 
min with 10% acetonitrile (solvent B) in 0.1 % formic acid (solvent A), a gradient up to 75 % acetonitrile within 143 
25 min was applied. Protein species were detected with a modified tune_high method of Bruker with the 144 
following settings adapted: mass range 350 – 3000 m/z, spectra rate 0.8 Hz, transfer time and ion cooler RF in 145 
basic stepping mode from 91 to 120 µs and from 450 to 700 Vpp, pre pulse storage 14 µs, low mass 400 m/z and 146 
in-source CID 30 Ev. Generated protein mass spectra were summed up in a range of 2 min and deconvoluted in 147 
Bruker’s Data Analysis 4.0 using maximum entropy charge deconvolution. 148 
 149 
Fractionation of O-glycopeptides 150 
For initial analysis, the c/MAM-domain (10 µg) was reduced, S-alkylated and digested either with sequencing 151 
grade modified trypsin (Promega, Madison, WI, USA) or chymotrypsin (Roche, Vienna, Austria) as described 152 
[16]. Subsequent analysis of the generated (glyco)peptides was done via reversed-phase LC-ESI-MS/MS with 153 
the said Dionex-HPLC and a maXis 4G Q-TOF MS (Bruker) [15]. For thorough O-glycopeptide analysis, 3 mg 154 
of S-alkylated c/MAM was digested with chymotrypsin (Roche, Vienna, Austria) overnight 37°C at a substrate 155 
to enzyme ration of 1:200. Peptides were fractionated on a BioBasic18 column (250 × 4 mm, 5 μm pore size, 156 
Thermo Scientific) with 1 mL / min flow rate with 65 mM ammonium formate of pH 3.0 as solvent A.  157 
Glycopeptides were collected in 1 min intervals between 14 and 27 % acetonitrile (solvent B) within 40 min. 158 
Fractions were dried in vacuum, taken up in 200 µL water and a 1 µL portion was analyzed via LC-ESI-MS with 159 
a very steep gradient to 75 % acetonitrile in 10 min (6 µl / min) on a capillary BioBasic18 column. 160 
Glycopeptides were detected with on an Ultima Global Q-TOF MS (Waters-Micromass, Manchester, UK).   161 
Fractions of interest were divided and either analyzed as such or after desialylation. To this end, 50 µL aliquots 162 
were dried and redissolved in 50 µL neuraminidase buffer (5 mM CaCl2 in 50 mM sodium acetate buffer, pH 163 
5.5) and digested with 1 µL (50 units) α2-3,6,8 neuraminidase (New England Biolabs, Frankfurt/Main, 164 
Germany) on 37 °C for 16 h. The glycopeptide species were subsequently purified using C-18 solid phase 165 
extraction cartridges (Hypersep C-18, 25 mg, Thermo Scientific). Conditioning was done with 500 µl 80% 166 
Acetonitrile (including 0.1 % formic acid) and two flushes with 500 µl 0.1 % formic acid. The samples were 167 
applied, washed once with 500 µl 0.1 % formic acid, eluted with 80% acetonitrile plus 0.1 % formic acid and 168 
dried in vacuum.  169 
 170 
6 
 
ETD analysis 171 
ETD-MS experiments of the fractions of interest were performed on a Bruker amaZon ion trap equipped with a 172 
nanoBooster CaptiveSpray source and prior LC separation. Glycopeptides were flushed onto a C-18 trapping 173 
column (C-18 PepMap100, 300 µm x 5 mm, Thermo Scientific, 20 µL / min flow rate), then applied to a 174 
separation column (Acclaim PepMap RSLC 75 µm x 250 mm, 2 µm, Thermo Scientific) at a flow rate of 300 175 
nL/min and eluted with a gradient from 13 to 40 % acetonitrile in 50 min. The electrospray settings were 1400 V 176 
capillary voltage, 500 V end plate offset, 0.2 bar nebulizer pressure, 3 L/min nitrogen gas flow and 150 °C 177 
drying gas temperature. The actual ETD reaction was done in Manual MS(n) mode with a 4 Da precursor 178 
selection window and ETD reagent times between 40 and 80 ms, depending on the precursor m/z and z values. 179 
The ETD data was processed in Data Analysis using the SNAP algorithm for generating average mass spectra of 180 
about 1-4 min (about 20-80 single ETD spectra), depending on the peak width. Other ETD settings, procedures 181 
and further data evaluation by BioTools 3.2 were done as described [15]. 182 
 183 
 184 
Results and Discussion 185 
 186 
Initial glycoproteomic analysis of c/MAM 187 
In SDS-PAGE the purified c/MAM domain exhibited an apparent mass of about 25 kDa, which considerable 188 
exceeds the expected 22 kDa (Supplementary Fig. 1). Glycosylation was assumed as the reason for this 189 
discrepancy. To get an impression of the degree of glycosylation the recombinant c/MAM domain was subjected 190 
to intact protein mass determination on a high-resolution Q-TOF instrument (Fig. 1). Intervals of 365 and 291 Da 191 
between major peaks indicated the complex pattern to be caused by differently glycosylated protein species. No 192 
unglycosylated c/MAM domain could be detected (22.308 kDa average mass, range not shown in Fig. 1). The 193 
mass differences between experimental peaks and the calculated protein mass suggested the attachment of 194 
several mucin type O-GalNAc glycans. To prove this hypothesis, O-glycans were released by reductive beta-195 
elimination, purified via SPE cartridges and analyzed by PGC-LC-ESI-MS/MS. The identified O-glycans were 196 
indeed mucin type core 1 and core 2 glycans (Figure 2) with different modifications and degree of terminal 197 
sialylation. The well characterized bovine fetuin O-glycans (singly and doubly sialylated core 1 and doubly 198 
sialylated core 2 O-glycans) were used as reference samples [17]. The c/MAM glycans not only showed the 199 
same retention behavior on the hypercarb column but also gave the same fragmentation pattern in the CID-200 
MS/MS spectra as the fetuin O-glycans (data not shown). Two peaks were obtained for a singly sialylated core 2 201 
glycan. Specific reporter ions in MS/MS spectra helped to resolve the main peak at 19.6 min as sialylated on the 202 
6-arm. The other glycan version with sialic acid on the 3-arm eluted some minutes earlier as had also been seen 203 
by Pabst et al. [18]. A very early eluting (8.1 min) monosialylated core 1 glycan (m/z 677.2, see Fig. 2) gave a 204 
fragment at 515 m/z (Neu5Ac-GalNAc-ol) in CID-MS/MS identifying the peak sialylated on the core-GalNAc 205 
residue rather than on the galactose. The fully sialylated core-2 glycan was also found sulfated, however, 206 
MS/MS in both positive and negative ion mode could not reveal the exact position of sulfation in the glycan. 207 
Further minor glycan structures (with an additional HexNAc attached to the GlcNAc) were proven by CID-208 
MS/MS, whereas the position of a fucose on yet another core-2 glycan could not be resolved.   209 
For further investigations of the complex glycosylation pattern and to prove that the modification sites are 210 
located in the region described in [10], the c/MAM domain was digested with different proteases and the 211 
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glycopeptides were characterized by RP-LC-ESI-CID-MS/MS. The use of the NetOGlyc 4.0 prediction tool for 212 
O-GalNac-glycosylation site mapping [10] suggested various amino acid candidates as being potentially 213 
modified. All of them were situated in the N-terminal part of the protein. Following protease treatment all 214 
peptides but the N-terminal peptide were identified as being non-glycosylated. The O-glycopeptide was, 215 
however, not found in a tryptic but in a chymotryptic digest, where glycan specific reporter ions (292, 366, etc.) 216 
in MS/MS spectra helped to identify the elution positions of the various glycoforms of the chymotryptic peptide 217 
ETGATEKPTVIDSTIQSEFPTY (Fig. 3). Other than with the fetuin O-glycopeptide, only one peak occurred per 218 
composition with the exception of gp336 and gp446. Nevertheless, preparative scale reversed phase fractionation 219 
of chymotryptic c/MAM-domain peptides was undertaken for sites specific glycosylation analysis by ETD-MS.   220 
Chymotryptic peptides were separated on a “preparative” column using a proportionally scaled up gradient as 221 
used for capillary LC-ESI-MS. For correct pooling, all fractions were inspected by LC-ESI-MS on the vintage 222 
2002 Micromass Ultima Q-TOF instrument. Interestingly, the amaZon ion trap equipped with the standard ESI 223 
source was not capable of detecting all glycopeptide forms. Especially peptides with a high glycan content - in 224 
particular sialic acid - could not be found.   225 
 226 
Determination of glycosylation sites and fine structure with ETD-MS 227 
A comparably poor performance of the ion trap was reported for synthetic sialylated N-glycopeptides [19]. In 228 
order to perform ETD-MS/MS on the amaZon ion trap, we aimed to find a solution for the said ionization 229 
problem with the standard ESI source that prevented ETD analysis of the more intensely glycosylated species in 230 
on-line LC and even in direct infusion mode. Nanospray LC-ESI with the nanoBooster CaptiveSpray source was 231 
recently reported to promote the ionization of (sialylated) glycopeptides [20]. In fact, the nanoBooster 232 
CaptiveSpray allowed ionization of all glyco-variants sufficiently well to obtain useful ETD spectra, however, 233 
with the heavily glycosylated forms only when desialylated. Fortunately, in the particular case of Nrp1 O-234 
glycosylation, desialylation did not lead to loss of information as all major structures were fully sialylated. With 235 
the Nrp1 glycopeptide being considerably smaller than the fetuin O-glycopeptide, ETD spectra could be obtained 236 
on an LC-ESI (rather than direct infusion) timescale using manual, targeted MS/MS mode, which permits dwell 237 
times of well over 1 min. 238 
Precursor charge state emerged as a most relevant criterion for ETD of other compounds [21, 22], it made little 239 
difference for Nrp1 glycopeptides. In contrast, co-eluting peptides severely affected ionization and hence 240 
fragmentation. Therefore, the prior fractionation step proved beneficial. Although nominally the same separation 241 
mechanism was applied, subtle differences in selectivity between preparative and analytical column led to more 242 
homogenous peaks on the latter.   243 
The smallest glycopeptide, gp112, could readily be elucidated as bearing it’s doubly sialylated core-1 glycan on 244 
T5. Gp224 was modified at T5 and T14 but not S13 as derived from the albeit small c13 ion (Fig. 4).  245 
With already six sialic acids, the poor ionization on the amaZon ion trap prevented gp336 ETD analysis and so it 246 
was the first glycopeptide subjected to desialylation by an α2-3,6,8 neuraminidase. Notably, only three sialic 247 
acids were removed this way – enough to provide a strong signal and ETD fragment spectra. At first, we 248 
regarded this partial desialylation as the incidental result of insufficient digestion conditions. However, the more 249 
highly sialylated structures exhibited an increasingly more complete removal of Neu5Ac with the core 2 type 250 
only species being fully desialylated. The overall pattern of incomplete desialylation compellingly implied that 251 
the GalNAc bound α2,6-Neu5Ac had resisted the neuraminidase treatment whereas the Gal-linked Neu5Ac 252 
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residues had been quantitatively removed. A PGC-LC-MS/MS measurement of neuraminidase treated, β-253 
eliminated O-glycans finally confirmed this hypothesis (Supplementary Fig. 2). 254 
Figure 5 gives an overview of the identified glycopeptide variants with glycans attached to specific amino acids. 255 
As mentioned before, glycopeptide forms with one or two glycans are always modified on T5 and T14, with T5 256 
being favored over T14. Glycopeptide forms with three modification sites (gp336, gp446 and gp666) showed 257 
always occupation at T5 and T14 while usage of T9 or S13 was variable. The differential modification of T9 or 258 
S13 in gp336 and gp446 led to the separation of distinct glycoforms in reversed phase chromatography. The 259 
early eluting peaks were modified at S13, whereas the later eluting peaks were glycosylated at T9. In contrast, 260 
the attachment of os222 on different residues in gp446 did not alter its elution behavior and produced only one 261 
peak (Fig.5). 262 
To conclude, four sites were used, i.e. T5, T9 S13 and T14 or T629, T633, S637 and T638 when counted in 263 
O14786 - NRP1_HUMAN (Fig.3). Interestingly, in gp666, gp778 and gp888, two rather bulky core-2 glycans 264 
were found on the neighboring amino acids S13 and T14.   265 
Three corresponding ETD spectra that were used for modification site determination are given in Figure 4A-C. 266 
The gp224 and gp666 (measured as gp660) spectra were chosen as representing one natural and one desialylated 267 
glycopeptide. In each case, the yield of c- and z-fragment ions was sufficient for assigning the exact 268 
glycosylation sites. In many glycopeptide spectra, a loss of some parts of a glycan during the ETD reaction could 269 
be observed. Loss of single sialic acids in natural glycopeptide samples or of HexNAc-Hex (366.1 [M+H]+ see 270 
figure 4) was observed. CID-like side reactions during ETD are known from literature [23, 24] and did not 271 
compromise the identification of glycan modification sites in any way. Figure 6c shows the ETD spectrum of 272 
gp334 that led to the identification of two different glycopeptide forms in the same sample. 273 
When comparing the detected glycosylated amino acids with those proposed as modified by the O-GalNAc-site 274 
prediction tool NetOGlyc 4.0, an over-estimation of glycosylation sites could be seen. The software assessed all 275 
actually glycosylated sites as positive, however, also the sites T2, S17 and T21 were predicted to be modified 276 
when having a look at recombinant c/MAM domain. With the complete neuropilin-1 sequence, T21 (T645 on 277 
NRP-1) was interestingly not suggested to be glycosylated. 278 
 279 
Substrate specificity of C. perfringens neuraminidase 280 
 281 
The hypothesis that neuraminidase disdains the GalNAc-linked Neu5Ac was tested with disialylated core 1 and 282 
core 2 O-glycans. In fact, the two Gal-linked sialic acids from core 2 glycans were readily removed and so was 283 
one Neu5Ac of the core 1 substrate (Supplementary Fig. 2). The remaining mono-sialylated structure was 284 
identified as Neu5Ac (Gal-)GalNAc by PGC-LC-MS/MS. In contrast to glycopeptide linked glycans, GalNAc-285 
linked sialic acid was degraded from free glycans but so much slower that this neuraminidases specificity can be 286 
useful for discrimination of differently linked sialic acid. 287 
288 
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Conclusion 289 
 290 
Recombinantly expressed neuropilin-1 c/MAM-domain was found to be heavily O-glycosylated in the region 291 
recently  reported as bearing several O-GalNAc residues when expressed in Simple Cells, which lack the ability 292 
to add the β1,3-Gal to the peptide bound GalNAc [10]. The main focus of this work was the comprehensive 293 
definition of the glycosylation sites and the attached glycans expressed by human cells with unquenched O-294 
glycosylation capability. The O-glycans found were all fully sialylated in contrast to e.g. fetuin [15] with one 295 
glycan being sulfated as well. 296 
ETD-MS proved its reputation for being the method of choice for this kind of analysis [25, 26], whereby the 297 
largest difficulty encountered with the highly sialylated neuropilin-1 glycopeptides was their poor ionization in 298 
the ESI source on the ion trap used for ETD.  299 
A glycopeptide species pyramid with the major glycopeptide gives an overview of the analytical results (Fig. 6). 300 
Four amino acids were identified to carry the O-glycan modifications (see Fig. 3 B).  301 
The isomers found suggest some hierarchy in the order of O-glycan addition. T5 was found modified in all cases 302 
and thus constituted the first target of a polypeptide GalNAc-transferase, strictly followed by T14. The other two 303 
glycosylation sites (T9 and S13) were not subject to such strict hierarchy and can be seen as equal O-glycan 304 
acceptors. As both core-1 and core-2 O-glycans were found on each of the four amino acids, no preference of the 305 
processing glycosyltransferases for a certain site - as was seen in other studies [15] - could be observed. The 306 
rather equal amounts of core-1 and core-2 glycans observed on c/MAM implies a balance between the sialylation 307 
reaction of a T-antigen structure and the buildup of a core-2 structure (addition of a GlcNAc onto the T-antigen) 308 
[27].  309 
The O-glycosylation region of neuropilin-1 is situated between two different outer membrane domains, the 310 
c/MAM domain and b2 domain [28]. Regarding the function of this O-glycosylation, it can only be speculated 311 
that the glycans may help this protein region to adopt the correct, stable conformation by forming a highly 312 
hydrophilic sleeve around the connecting peptide stretch.  Another interesting fact is that a described 313 
glycosaminoglycan modification [3], known to influence VEGF signaling, is only 16 aa upstream of the first 314 
detected O-GalNAc modification site. Thus, the heavy O-GalNAc glycosylation in this part may also play some 315 
role in binding VEGFR2 or other binding partners as galectin-1. Certainly, future studies will have to illuminate 316 
the probable functions of this novel glycosylation. 317 
Finally, two technical aspects shall be emphasized. First, very unlike N-glycopeptides of different glycan 318 
structure [16, 29], O-glycopeptides of differing composition exhibit a large spread of elution times as seen with 319 
fetuin and again in this study. 320 
Second, the (recombinant) sialidase from Clostridium perfringens exhibited an as yet unnoticed substrate 321 
specificity in being almost inactive towards the GalNAc-linked α2,6-neuraminic acid in O-glycopeptides.  322 
  323 
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Figure legends: 405 
 406 
Fig. 1:  Total mass determination of recombinant neuropilin-1 c/MAM domain. Deconvoluted average mass 407 
spectrum of c/MAM glycoprotein species. The most intense protein forms were named according to the number 408 
of attached N-acetylhexosamine, hexose and sialic acid sugars. Peaks marked with the same color were found to 409 
carry different O-glycans on the same amino acid side chains (see also figure 4 and 5). c/MAM glycoprotein was 410 
also found truncated of the first N-terminal four amino acids (ETGA - see peak gp224*). 411 
 412 
 413 
Fig. 2: Analysis of released O-glycans. Reduced O-glycans as obtained by reductive β-elimination were 414 
separated by PGC-LC and detected by mass spectrometry. 415 
 416 
 417 
Fig. 3: Variety of neuropilin-1 O-glycopeptides. The chymotryptic O-glycopeptide of neuropilin-1 c/MAM 418 
domain was subjected to RP-LC-ESI-MS with detection by a Q-TOF Ultima MS (Waters Micromass). 419 
Panel A depicts the extracted ion chromatograms for the major compositions illustrating the largely different 420 
retention as caused by different glycosylation. Only two compositions eluted in more than one peak. Panel B 421 
shows the amino acid sequences of chymotryptic N-terminal glycopeptide of the recombinant neuropilin-1 422 
c/MAM-domain and the corresponding neuropilin-1 Uniprot entry (O14786 - NRP1_HUMAN). Residues 423 
marked in red were found to be O-glycosylated. 424 
 425 
 426 
Fig. 4: Summed ETD spectra of gp224 (a), the desialylated gp660 (b) and gp334 (c). Identified c- and z-427 
fragment ions are marked in red and blue. Confirmed glycopeptide forms are shown in the upper right corner of 428 
the graphs with all corresponding fragment ions depicted in red. In part c, two different glycopeptide variants 429 
could be identified (marked with * and °). Fragment ions that discriminate between these forms in the graph are 430 
as well marked with * and °.  431 
 432 
 433 
Fig. 5: Glycopeptide species of the neuropilin-1 c/MAM domain of recombinant illuminated with ETD-434 
MS. Glycopeptide variants with exclusively core 1 O-glycans are listed in the left column. Forms with core 2 435 
glycans only are displayed at the right side, whereas the variants with both types of core structures are shown in 436 
the middle. Forms marked in blue (e.g. gp448) were analyzed after desialylation. As all the major forms 437 
considered for determination of exact site occupancy were doubly sialylated (see Fig. 1), the full sialylation 438 
regalia of these glycopeptides could be re-constructed as shown. Glycan modifications on S13 and T14 could not 439 
be resolved in all glycopeptide species, ambiguities are marked with a line (e.g. gp558). Gp446 marked with a * 440 
could not be definitely confirmed or excluded. 441 
 442 
 443 
Fig. 6: Glycopeptide pyramide. The top field shows the relevant part of c/MAM in its unglycosylated state that 444 
was, however, not observed. The numbers in red represent c/MAM-peptides with the respective number of sugar 445 
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residues attached, whereby 224 indicates the presence of 2 HexNAc (1 GalNAc, 1 GlcNAc), 2 galactoses and 4 446 
sialic acid residues. Going down one level one O-glycan is attached at its step. If the direction points to the left, a 447 
112 core 1 glycan is added, if to the left, a 222 core 2 glycan is attached. The colored fields contain peptides with 448 
the same number of O-glycan moieties. The glycan attachment sites in the peptides are marked in red.     449 
 450 
Supplementary Fig. 1: Quality control of purified recombinant c/MAM domain. Size exclusion 451 
chromatography and SDS-PAGE demonstrate high protein purity and an apparent size of ~ 25 kDa.  452 
 453 
Supplementary Fig. 2: Proof of novel α2-3,6,8 neuraminidase substrate specificity. Panel A shows the 454 
chromatograms of the two main O-glycan species, derived from reductive beta elimination of neuraminidase 455 
treated chymotryptic recombinant neuropilin-1. The structure of the core 1 glycan was verified by positive mode 456 
CID fragmentation, giving the feature ion 515.1 m/z (panel B). Panel C shows a CID fragmentation spectrum of 457 
the main fetuin O-glycan being sialylated on the galactose. In contrast to panel C, 515 m/z shows no signal 458 
whereas a specific feature ion at 454.1 m/z (Neu5Ac-Gal) appears.  459 
  460 
  461 
15 
 
Fig. 1: 462 
 463 
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Fig. 2: 465 
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Fig. 3: 467 
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Fig. 5: 475 
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Fig. 6: 478 
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Supplementary Fig. 1: 481 
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Supplementary Fig. 2: 484 
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